Cameron Turtle

Chief Strategy Officer at BridgeBio

Cameron Turtle, Ph.D. has served as our Chief Strategy Officer since January 2021. Prior to that, he served as our Senior Vice President, Portfolio Management and Corporate Development, from January 2018 until December 2020 and served as a Director, Portfolio Management, from February 2017 to December 2017. Dr. Turtle has also worked for our subsidiary, Eidos Therapeutics, since February 2017, as the chief business officer, and currently serves as a director of certain of our subsidiaries, including Aspa Therapeutics, since June 2018, CoA Therapeutics, Inc. since January 2018, Dermecular since July 2017 and Fortify Therapeutics since December 2017. Dr. Turtle previously worked as vice president of business development and operations for our subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017, Dr. Turtle was a consultant at McKinsey & Company. Dr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John’s College, where he was a Rhodes Scholar.

Links


Org chart

Sign up to view 0 direct reports

Get started